Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Fmr LLC

Fmr LLC boosted its position in shares of Adicet Bio, Inc. (NASDAQ:ACET) by 31.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 276,169 shares of the company’s stock after buying an additional 65,903 shares during the period. Fmr LLC owned 0.34% of Adicet Bio worth $398,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. American Century Companies Inc. lifted its stake in shares of Adicet Bio by 22.9% in the second quarter. American Century Companies Inc. now owns 76,087 shares of the company’s stock worth $92,000 after buying an additional 14,196 shares in the last quarter. Point72 DIFC Ltd raised its holdings in Adicet Bio by 77.5% in the 2nd quarter. Point72 DIFC Ltd now owns 33,441 shares of the company’s stock valued at $40,000 after acquiring an additional 14,596 shares during the last quarter. GSA Capital Partners LLP lifted its stake in Adicet Bio by 161.3% in the 3rd quarter. GSA Capital Partners LLP now owns 39,208 shares of the company’s stock worth $56,000 after purchasing an additional 24,203 shares in the last quarter. XTX Topco Ltd boosted its holdings in shares of Adicet Bio by 14.9% during the 2nd quarter. XTX Topco Ltd now owns 259,788 shares of the company’s stock worth $314,000 after purchasing an additional 33,739 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Adicet Bio in the second quarter valued at approximately $43,000. Institutional investors and hedge funds own 83.89% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on ACET. HC Wainwright reiterated a “neutral” rating on shares of Adicet Bio in a research report on Thursday. Canaccord Genuity Group reduced their price target on Adicet Bio from $19.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, September 11th. StockNews.com lowered shares of Adicet Bio from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. Guggenheim assumed coverage on shares of Adicet Bio in a research note on Monday, September 30th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $5.00 target price on shares of Adicet Bio in a report on Thursday, November 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Adicet Bio presently has an average rating of “Hold” and an average price target of $7.50.

Adicet Bio Trading Down 4.0 %

NASDAQ ACET opened at $0.86 on Friday. The stock has a fifty day simple moving average of $1.17 and a 200-day simple moving average of $1.32. The stock has a market cap of $70.86 million, a PE ratio of -0.50 and a beta of 1.88. Adicet Bio, Inc. has a twelve month low of $0.81 and a twelve month high of $3.77.

Adicet Bio (NASDAQ:ACET) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, hitting the consensus estimate of ($0.34). Research analysts predict that Adicet Bio, Inc. will post -1.39 EPS for the current year.

Adicet Bio Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.